Oncotelic Therapeutics, Inc NT 10-K, filed Apr 1, 2021
Oncotelic Therapeutics, Inc. (OTLC)
NT 10-K
2021-04-01
For: 2020-12-31
View Original
Added on
October 17, 2026
| OMB APPROVAL | ||
OMB Number: 3235-0058 |
||
Expires: October 31, 2018 |
||
Estimated average burden hours per response ... 2.50 |
||
| SEC FILE NUMBER | ||
001-21990 |
||
| CUSIP NUMBER | ||
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check one):
[ x ] Form 10-K
[ ] Form 20-F
[ ] Form 11-K
[ ] Form 10-Q
[ ] Form 10-D
[ ] Form N-SAR
[ ] Form N-CSR
For Period Ended: December 31, 2020
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
Oncotelic Therapeutics, Inc.
Full Name of Registrant
Former Name if Applicable
29397 Agoura Road Suite 107
Address of Principal Executive Office (Street and Number)
Agoura Hills, California, 91301
City, State and Zip Code
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
[ x ]
|
|||||
| (a) | The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense | ||||
| (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and | ||||
| (c) | The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III - NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
Oncotelic Therapeutics, Inc. ("Oncotelic" or "Our") is unable to file, without unreasonable effort or expense, our Annual Report on Form 10-K ("Form 10-K") for the year ended December 31, 2020 by the prescribed filing date because it is still in the process of completing its audit of the financial statements required to be included in the Form 10-K. Oncotelic currently expects that it will be able to complete the audit necessary in time for the Company to file the Form 10-K within the fifteen calendar day extension provided by Rule 12b-25.
| Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
(Attach extra Sheets if Needed)
PART IV - OTHER INFORMATION
PART IV - OTHER INFORMATION
| (1) | Name and telephone number of person to contact in regard to this notification |
| Amit Shah | 650 | 635-7000 | ||
(Name) |
(Area Code) | (Telephone Number) |
| (2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). | |
| Yes[ x ] No[ ] | ||
| (3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? | |
| Yes[ ] No[ x ] | ||
| If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. | ||
Oncotelic Therapeutics, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 31, 2021
| By: | /s/ Amit Shah |
| Name: Amit Shah | |
| Title: Chief Financial Officer |